Kazia Therapeutics Ltd ADR美股招股说明书(2026-03-19版)

Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December23, 2025 (the“Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No.333-292303), with the information contained in ourcurrent report on Form 6-K, furnished to the Securities and Exchange Commission on March19, 2026 (the “March 19, 2026 Form 6-K”). Accordingly,we have attached the March19, 2026 Form 6-K to this prospectus supplement. This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered orutilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read inconjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you shouldrely on the information in this prospectus supplement. The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On March18, 2026, the last reported sale price of the ADSson Nasdaq was $7.51 per ADS. Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 of the Prospectus andthe “Risk Factors” in “Item 3. Key Information-D. Risk Factors” of our most recent Annual Report on Form 20-F,which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in anyapplicable prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passedupon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level24 300 Barangaroo Avenue Sydney NSW 2000(Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F☒Form 40-F☐ INFORMATION CONTAINED IN THIS FORM 6-K REPORT On March16, 2026 AEDT, Kazia Therapeutics Limited (the “Company”) reported its unaudited half-year results for the sixmonths endedDecember31, 2025, a copy of which is attached to this Form 6-K as Exhibit 99.1. EXHIBIT LIST SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by theundersigned, thereunto duly authorized. Kazia Therapeutics Limited(Registrant) Kazia Therapeutics LimitedABN 37 063 259 754Half Yearly Report - 31December 2025 Kazia Therapeutics LimitedDirectors’ report31 December 2025 The directors present their report, together with the financial statements, on the Consolidated entity (referred to hereafter as the ‘Consolidated entity’)consisting of Kazia Therapeutics Limited (referred to hereafter as the ‘Consolidated entity’ or ‘parent entity’) and the entities it controlled at the end of,or during, the half-year ended 31December 2025. Directors The following persons were directors of Kazia Therapeutics Limited during the whole of the financial year and up to the date of this report, unlessotherwise stated: Dr John FriendBryce CarmineSteven CoffeyEbru DavidsonRobert Apple Principal activities During the financial year the principal continuing activity of the Consolidated entity consisted of pharmaceutical research and development with a viewto commercialising the results of our research through license transactions or other means. Review of operations The loss for the Consolidated entity after providing for income tax amounted to $12,552,490 (31December 2024: $10,453,811). The attached financial statements detail the performance and financial position of the Consolidated entity for the half-year ended 31December 2025. Cash resources At 31December 2025, the Consolidated entity had total funds of $69,459,980 comprising cash in hand and at bank. Going concern For the period ended 31December 2025 the Consolidated Entity incurred a loss after income tax of $12,552,490 (31December 2024: $10,453,811), wasin a net current asset position of $45,612,689 (30June 2025 net current liability: $9,119,727) and had net cash outflows from operating activities of$9,540,623 (31December 2024: $8,420,244) for the half-year ended 31December 2025. The Directors note the following with regards to the ability of the Consolidated Entity to continue as a going concern: •During the period, the Company received notifications from Nasdaq regarding non-compliance with t